Skip to content

Study · Animal study (in vivo) · mouse · 2015

2 results

Efficiency of recombinant thymosin β4 in spontaneous mouse model of chronic dermatitis.

Moiseeva EV, Beirakhova KA, Semushina SG, Aronov DA, Makarov DA, Esipov RS

Bulletin of experimental biology and medicine17 Mar 2015Cited by 1 (Europe PMC)

PMID25778656 (opens in a new tab)DOI10.1007/s10517-015-2831-y (opens in a new tab)PepBankPUB-25778656
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In female CBRB mice with chronic dermatitis, three applications of recombinant Tβ4 during a week significantly alleviated symptoms.

    In plain wordsIn mice with chronic skin inflammation, recombinant Tβ4 applied three times in a week eased the symptoms.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseDermatitis symptoms after three applications
    Study

    mousen: not reported in source

    Spontaneous CBRB mouse model of chronic dermatitis
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated · three applications during a weekAs given in this study (mouse).

    Source sentences

    Summary
    Three applications of the drug during a week significantly alleviated symptoms of the disease in female mice
    1 context sentence
    Summary · context
    The therapeutic efficiency of recombinant thymosin β4 (rTβ4) synthesized by us was studied in vivo on spontaneous CBRB mouse model that is adequate to human chronic dermatitis.

Studies that did not test the peptide alone1

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 02AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    In female CBRB mice with chronic dermatitis, recombinant Tβ4 followed by antibacterial and antifungal therapy gave a pronounced therapeutic effect lasting 2 months.

    In plain wordsIn mice with chronic skin inflammation, Tβ4 followed by antibacterial and antifungal treatment gave a lasting effect of 2 months.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseDermatitis symptoms with Tβ4 plus antibacterial and antifungal therapy
    Study

    mousen: not reported in source

    Spontaneous CBRB mouse model of chronic dermatitis
    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    in complex with subsequent antibacterial and antifungal therapy led to a pronounced and lasting (2 months) therapeutic effect.
    1 context sentence
    Summary · context
    The therapeutic efficiency of recombinant thymosin β4 (rTβ4) synthesized by us was studied in vivo on spontaneous CBRB mouse model that is adequate to human chronic dermatitis.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.